thermis medicare-related companies

This company's strategy is in some ways very similar to POH ie taking existing active already approved by FDA.

Jaleva's patented resin technology allows medication to be delivered safely and more effectively to the skin and through the skin than traditional delivery vehicles. Jaleva's resin technology is a formulation of specific resins which combine with medication or an active ingredient. The formulation is applied topically on the skin or trans-mucosally and releases the medication over time.

Upcoming Products in Development

The next several products on our agenda for development and licensing are:

- A Nicotine Replacement Therapy product - with a low Tmax (10 min) when compared to gums / lozenges.

- A topical Ibuprofen product

- A topical Diclofenac product

Partnering strategy/interests
Jaleva is engaged in the research & development of topical delivery and trans-mucosal vehicles for active ingredients that treat:

smoking cessation, pain (using Ibuprofen), acne, psoriasis, heel fissures (cracked heels), athletes foot, sunscreen, surgical applications, topical anesthetics and other dermatological conditions.

We seek to license or partner with a firm that has a desire to market almost any dermatology topical medication with our superior delivery system of the active ingredient.

Our FDA routes are short since we typically enter a marketplace with an active ingredient already approved by the FDA.

Our IP is strong and covers our technology broadly.